| Ticker Details |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
|
| IPO Date: |
May 28, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$42.87B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.79 | 2.18%
|
| Avg Daily Range (30 D): |
$4.72 | 1.48%
|
| Avg Daily Range (90 D): |
$5.70 | 1.58%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.56M |
| Avg Daily Volume (30 D): |
.89M |
| Avg Daily Volume (90 D): |
1.12M |
| Trade Size |
| Avg Trade Size (Sh.): |
74 |
| Avg Trade Size (Sh.) (30 D): |
29 |
| Avg Trade Size (Sh.) (90 D): |
33 |
| Institutional Trades |
| Total Institutional Trades: |
10,930 |
| Avg Institutional Trade: |
$8.14M |
| Avg Institutional Trade (30 D): |
$26.84M |
| Avg Institutional Trade (90 D): |
$39.86M |
| Avg Institutional Trade Volume: |
.05M |
| Avg Institutional Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$14.78M |
| Avg Closing Trade (30 D): |
$62.53M |
| Avg Closing Trade (90 D): |
$85.6M |
| Avg Closing Volume: |
86.39K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$2.39
|
$.84
|
$2.39
|
|
Diluted EPS
|
$2.33
|
$.82
|
$2.33
|
|
Revenue
|
$3.71B
|
$1.1B
|
$3.71B
|
|
Gross Profit
|
$3.04B
|
$829.31M
|
$3.04B
|
|
Net Income / Loss
|
$313.75M
|
$111.54M
|
$313.75M
|
|
Operating Income / Loss
|
$501.58M
|
$131.72M
|
$501.58M
|
|
Cost of Revenue
|
$677.17M
|
$267.72M
|
$677.17M
|
|
Net Cash Flow
|
$690.16M
|
$166.01M
|
$690.16M
|
|
PE Ratio
|
138.24
|
|
|
|
|
|
